Cost-effectiveness of screening and treating Helicobacter pylori for gastric cancer prevention
MetadataShow full item record
Gastric cancer is the second leading cause of cancer-related death worldwide. A meta-analysis of seven randomized controlled trials concluded that Helicobacter pylori eradication reduces gastric cancer incidence by 35%. Current consensus is that H. pylori screening and treatment is cost-effective only in high-risk populations. This paper provides an up-to-date overview of the evidence for cost-effectiveness of H. pylori screening and treatment in different population settings and risk levels for H. pylori infection. Ten unique cost-effectiveness or cost-utility analyses were identified. All found that screening for H. pylori to prevent gastric cancer in the general population costs less than $50,000 per LYG. This finding was robust for differences in H. pylori prevalence, gender and ethnicity. Based on limited evidence, re-treatment (for treatment failure), repeated screening, limiting screening and treatment to those with the CagA phenotype, or universal treatment, does not appear to be cost-effective. However, most included studies failed to consider both the broader benefits as well as the adverse effects of widespread use of antibiotics for H. pylori.
Showing items related by title, author, creator and subject.
Schulte, A.; Pandeya, N.; Fawcett, J.; Fritschi, Lin; Risch, H.; Webb, P.; Whiteman, D.; Neale, R. (2015)Purpose: Gastric colonization with Helicobacter pylori (H. pylori) has been implicated in the pathogenesis of pancreatic cancer, but results of epidemiological studies have been inconclusive. We analyzed data from the ...
Lansdorp_Vogelaar, Iris; Knudsen, A.; Brenner, H. (2011)Colorectal cancer is an important public health problem. Several screening methods have been shown to be effective in reducing colorectal cancer mortality. The objective of this review was to assess the cost-effectiveness ...
Personalizing Colonoscopy Screening for Elderly Individuals Based on Screening History, Cancer Risk, and Comorbidity Status Could Increase Cost EffectivenessVan Hees, F.; Saini, S.; Lansdorp_Vogelaar, Iris; Vijan, S.; Meester, R.; De Koning, H.; Zauber, A.; Van Ballegooijen, M. (2015)Background and Aims Colorectal cancer (CRC) screening decisions for elderly individuals are often made primarily on the basis of age, whereas other factors that influence the effectiveness and cost effectiveness of screening ...